Antigen-independent tumor targeting by CBX-12 (alphalex™–exatecan) induces long-term antitumor immunity
Gayle S, Paradis T, Jones K, Vasquez J, Paralkar V. Antigen-independent tumor targeting by CBX-12 (alphalex™–exatecan) induces long-term antitumor immunity. Immunotherapy 2022, 14: 1467-1480. PMID: 36597724, DOI: 10.2217/imt-2022-0121.Peer-Reviewed Original ResearchConceptsLong-term antitumor immunityAntitumor immunityImmune recognition of tumor cellsInducer of immunogenic cell deathRecognition of tumor cellsAnti-PD-1Immunogenic cell deathDelayed tumor growthExpression of MHC-1Immunotherapy combinationsPH-sensitive peptidesComplete responseCT26 modelPD-L1Tumor cellsTumor targetingTumor growthCured animalsClinical trialsELISA assayImmunotherapyMHC-1Cell deathFunctional assaysImmunityTOP1-DNA Trapping by Exatecan and Combination Therapy with ATR Inhibitor.
Jo U, Murai Y, Agama KK, Sun Y, Saha LK, Yang X, Arakawa Y, Gayle S, Jones K, Paralkar V, Sundaram RK, Van Doorn J, Vasquez JC, Bindra RS, Choi WS, Pommier Y. TOP1-DNA Trapping by Exatecan and Combination Therapy with ATR Inhibitor. Molecular Cancer Therapeutics 2022, 21: 1090-1102. PMID: 35439320, PMCID: PMC9256811, DOI: 10.1158/1535-7163.mct-21-1000.Peer-Reviewed Original ResearchConceptsATR inhibitorsTop1 inhibitorsHomologous recombination deficiencyNovel molecular interactionApoptotic cell deathCancer cellsTop1 cleavage complexesAtaxia telangiectasiaCleavage complexesCell deathDNA damageHigher DNA damageMolecular interactionsDNA baseKinase inhibitorsI inhibitorMolecular pharmacologyMouse xenograftsTOP1Recombination deficiencyTopoisomerase I inhibitorInhibitorsTumor growthRad3Predictive biomarkers